Clinical Trials
11 trialsNCT05386108 2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT07098806 2025-08-01
CA2024-LM-001
Plus Therapeutics
Phase 1 Recruiting
NCT02766699 2025-06-03
CerebralEDV
Engeneic Pty Limited
Phase 1 Completed
NCT05664243 2025-05-01
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
In8bio Inc.
Phase 1/2 Active not recruiting
NCT05241873 2025-02-10
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
Phase 1 Terminated
NCT03150862 2025-02-04
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
BeiGene
Phase 1/2 Completed
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT03424473 2020-02-25
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Seagen Inc.
No longer available
NCT01386580 2015-01-22
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
BBB-Therapeutics B.V.
Phase 1/2 Completed